Publications by authors named "Run Zhuang"

Claim this Profile
U
Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease.
Deli Wang, Hana Florian, Shau-Yu Lynch, Weining Robieson, Run Zhuang

Alzheimers Dement (N Y)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychiatric service dog placements are associated with better daily psychosocial functioning for military veterans with posttraumatic stress disorder.
Sarah C Leighton, Kerri E Rodriguez, Run Zhuang, Clare L Jensen, Elise A Miller

Psychol Trauma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CITIES: Clinical trials with intercurrent events simulator.
Ahmad Hakeem Abdul Wahab, Yongming Qu, Hege Michiels, Junxiang Luo, Run Zhuang

Biom J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cortisol awakening response in a 3 month clinical trial of service dogs for veterans with posttraumatic stress disorder.
Leanne O Nieforth, Kerri E Rodriguez, Run Zhuang, Elise A Miller, Arman Sabbaghi

Sci Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physicians' very brief (30-sec) intervention for smoking cessation on 13 671 smokers in China: a pragmatic randomized controlled trial.
Yee Tak Derek Cheung, Nan Jiang, Chao Qiang Jiang, Run Sen Zhuang, Wen Hui Gao, Zhuang Hong Huang

Addiction· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
Sean P Brown, Paul Dransfield, Marc Vimolratana, Liusheng Zhu, Jian Luo, Run Zhuang

ACS Med Chem Lett· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
Zhengjia Chen, Zheng Li, Run Zhuang, Ying Yuan, Michael Kutner

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the imidazole-derived GPR40 agonist AM-3189.
Zhihua Ma, Daniel C-H Lin, Rajiv Sharma, Jinqian Liu, Liusheng Zhu, Run Zhuang

Bioorg Med Chem Lett· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of GPR40 Agonists for Type 2 Diabetes.
Jiwen Jim Liu, Yingcai Wang, Zhihua Ma, Mike Schmitt, Liusheng Zhu, Run Zhuang

ACS Med Chem Lett· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
Xiaohui Du, Paul J Dransfield, Daniel C-H Lin, Simon Wong, Yingcai Wang, Run Zhuang

ACS Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
Ming Yu, Mike Lizarzaburu, Alykhan Motani, Zice Fu, Xiaohui Du, Run Zhuang

ACS Med Chem Lett· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
Narihiro Toda, Xiaolin Hao, Yasuyuki Ogawa, Kozo Oda, Ming Yu, Run Zhuang

ACS Med Chem Lett· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
Jian Luo, Gayathri Swaminath, Sean P Brown, Jane Zhang, Qi Guo, Run Zhuang

PLoS One· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
Yingcai Wang, Jiwen Jim Liu, Paul J Dransfield, Liusheng Zhu, Zhongyu Wang, Run Zhuang

ACS Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
Sean P Brown, Paul J Dransfield, Marc Vimolratana, XianYun Jiao, Liusheng Zhu, Run Zhuang

ACS Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
Daniel C-H Lin, Jane Zhang, Run Zhuang, Frank Li, Kathy Nguyen

PLoS One· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
cis-Retinol/androgen dehydrogenase, isozyme 3 (CRAD3): a short-chain dehydrogenase active in a reconstituted path of 9-cis-retinoic acid biosynthesis in intact cells.
Run Zhuang, Min Lin, Joseph L Napoli

Biochemistry· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis